Dalpiciclib: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Dalpiciclib

• Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
  NCT06149130 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
  NCT06107673 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
  NCT07492394 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Dalpiciclib in HR+/HER2- ABC
  NCT06301438 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
  NCT07610720 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
  NCT06341894 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
  NCT05578053 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
  NCT05759546 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
  NCT05638594 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• SNF Platform Study of HR+/ HER2-advanced Breast Cancer
  NCT05594095 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location

Common questions

How many recruiting trials involve Dalpiciclib?

11 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.